Abstract

Even though vaccination has started against COVID-19, people should continue maintaining personal and social caution as it takes months or years to get everyone vaccinated, and we are not sure how long the vaccine remains efficacious. In order to contribute to the mitigation of COVID-19 symptoms, the pharmaceutical industry aims to develop antiviral drugs to inhibit the SARS-CoV-2 replication and produce anti-inflammatory medications that will inhibit the acute respiratory distress syndrome (ARDS), which is the primary cause of mortality among the COVID-19 patients. In reference to these tasks, this article considers the properties of a medicinal plant named licorice (Glycyrrhiza glabra), whose phytochemicals have shown both antiviral and anti-inflammatory tendencies through previous studies. All the literature was selected through extensive search in various databases such as google scholar, Scopus, the Web of Science, and PubMed. In addition to the antiviral and anti-inflammatory properties, one of the licorice components has an autophagy-enhancing mechanism that studies have suggested to be necessary for COVID-19 treatment. Based on reviewing relevant professional and historical literature regarding the medicinal properties of licorice, it is suggested that it may be worthwhile to conduct in vitro and in vivo studies, including clinical trials with glycyrrhizic and glycyrrhetinic acids together with other flavonoids found in licorice, as there is the potentiality to provide natural interventions against COVID-19 symptoms.

Highlights

  • The coronavirus disease (COVID-19), which began in the city of Wuhan in the Peoples’ Republic of China (PRC) during the last quarter of 2019, quickly moved to Europe and the USA and subsequently into the Asian and African countries

  • In the absence of any suitable pharmaceutical intervention in western medicine to treat COVID-19 patients, the objective of this review is to highlight the potential of a medicinal plant species, commonly called licorice (Glycyrrhiza glabra), which belongs to the shrub category, whose phytochemicals have antiviral and anti-inflammatory properties, and to suggest that clinical trials be introduced to assess its potency regarding COVID-19

  • COVID-19 is spreading across the world with several thousand deaths every day and it is hitting many places as a secondary and tertiary waves

Read more

Summary

Introduction

The coronavirus disease (COVID-19), which began in the city of Wuhan in the Peoples’ Republic of China (PRC) during the last quarter of 2019, quickly moved to Europe and the USA and subsequently into the Asian and African countries This severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of people worldwide and has taken more than 5 million lives as of the end of October 2021 [1]. As a result of these disruptions, many people struggle to find income to support their families, and several national and state governments have been required to ensure sufficient revenue flow within their communities This situation will only be relieved with the development and availability of symptomatic control medicines or by vaccinating the whole world against all the existing and potential strains. The presence of hundreds of thousands of breakthrough cases highlights the significance of pharmacological interventions to treat COVID-19 cases

Objectives
Methods
Findings
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.